{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01781637",
      "orgStudyIdInfo": {
        "id": "Peanut 002"
      },
      "organization": {
        "fullName": "Boston Children's Hospital",
        "class": "OTHER"
      },
      "briefTitle": "Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial",
      "officialTitle": "Phase 2 Study of Omalizumab in Oral Peanut Desensitization",
      "acronym": "PRROTECT"
    },
    "statusModule": {
      "statusVerifiedDate": "2023-02",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2013-01"
      },
      "primaryCompletionDateStruct": {
        "date": "2015-10",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2022-05-31",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2013-01-30",
      "studyFirstSubmitQcDate": "2013-01-31",
      "studyFirstPostDateStruct": {
        "date": "2013-02-01",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2017-03-23",
      "resultsFirstSubmitQcDate": "2017-03-23",
      "resultsFirstPostDateStruct": {
        "date": "2017-05-03",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2023-02-16",
      "lastUpdatePostDateStruct": {
        "date": "2023-02-21",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "PRINCIPAL_INVESTIGATOR",
        "investigatorFullName": "Lynda Schneider",
        "investigatorTitle": "Professor, Harvard Medical School",
        "investigatorAffiliation": "Boston Children's Hospital"
      },
      "leadSponsor": {
        "name": "Boston Children's Hospital",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Children's Hospital of Philadelphia",
          "class": "OTHER"
        },
        {
          "name": "Stanford University",
          "class": "OTHER"
        },
        {
          "name": "Ann & Robert H Lurie Children's Hospital of Chicago",
          "class": "OTHER"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": true
    },
    "descriptionModule": {
      "briefSummary": "The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.",
      "detailedDescription": "36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital.\n\nPatients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization. Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization, receiving their final dose of Xolair one week after reaching the highest tolerated dose of peanut."
    },
    "conditionsModule": {
      "conditions": [
        "Peanut Allergy",
        "Food Allergy"
      ],
      "keywords": [
        "Xolair",
        "omalizumab",
        "peanut",
        "oral desensitization"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "QUADRUPLE",
          "whoMasked": [
            "PARTICIPANT",
            "CARE_PROVIDER",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 36,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "omalizumab group",
          "type": "EXPERIMENTAL",
          "description": "Patients will receive omalizumab.",
          "interventionNames": [
            "Drug: Omalizumab"
          ]
        },
        {
          "label": "placebo",
          "type": "PLACEBO_COMPARATOR",
          "description": "Patients will receive placebo.",
          "interventionNames": [
            "Drug: placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Omalizumab",
          "description": "subcutaneous injection",
          "armGroupLabels": [
            "omalizumab group"
          ],
          "otherNames": [
            "Xolair"
          ]
        },
        {
          "type": "DRUG",
          "name": "placebo",
          "description": "subcutaneous injection",
          "armGroupLabels": [
            "placebo"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo",
          "timeFrame": "6 weeks after last dose of omalizumab/placebo"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo",
          "timeFrame": "12 weeks after last dose of omalizumab/placebo"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25 years old.\n* Sensitivity to peanut allergen will be documented by a positive skin prick test result (6 mm diameter wheal or greater)\n* ImmunoCAP IgE level to peanut \\> 10 kU/L.\n* Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.\n\nExclusion Criteria:\n\n* Subjects with a total IgE at screening of \\< 50 kU/L \\> 2,000 kU/L.\n* Positive reaction to the placebo on DBPCFC.\n* Previous reaction to omalizumab.\n* Subjects having a history of severe anaphylaxis to peanut requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma, or gastrointestinal or gastroesophageal disease.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "7 Years",
      "maximumAge": "25 Years",
      "stdAges": [
        "CHILD",
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Lynda C Schneider, MD",
          "affiliation": "Boston Children's Hospital",
          "role": "PRINCIPAL_INVESTIGATOR"
        },
        {
          "name": "Andrew MacGinnitie, MD, PhD",
          "affiliation": "Children' Hospital Boston",
          "role": "STUDY_CHAIR"
        },
        {
          "name": "Kari Nadeau, MD, PhD",
          "affiliation": "Stanford University",
          "role": "STUDY_CHAIR"
        },
        {
          "name": "Jonathan Spergel, MD, PhD",
          "affiliation": "Children's Hospital of Philadelphia",
          "role": "STUDY_CHAIR"
        },
        {
          "name": "Jacqueline Pongracic, MD",
          "affiliation": "Lurie Children's Hospital",
          "role": "STUDY_CHAIR"
        }
      ],
      "locations": [
        {
          "facility": "Stanford University",
          "city": "Stanford",
          "state": "California",
          "zip": "94305",
          "country": "United States",
          "geoPoint": {
            "lat": 37.42411,
            "lon": -122.16608
          }
        },
        {
          "facility": "Lurie Children's Hospital",
          "city": "Chicago",
          "state": "Illinois",
          "zip": "60611",
          "country": "United States",
          "geoPoint": {
            "lat": 41.85003,
            "lon": -87.65005
          }
        },
        {
          "facility": "Division of Immunology, Children's Hospital Boston",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02115",
          "country": "United States",
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "Children's Hospital of Philadelphia",
          "city": "Philadelphia",
          "state": "Pennsylvania",
          "zip": "19104",
          "country": "United States",
          "geoPoint": {
            "lat": 39.95238,
            "lon": -75.16362
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "34755130",
          "type": "DERIVED",
          "citation": "Chen G, Shrock EL, Li MZ, Spergel JM, Nadeau KC, Pongracic JA, Umetsu DT, Rachid R, MacGinnitie AJ, Phipatanakul W, Schneider L, Oettgen HC, Elledge SJ. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy. Cell Rep Med. 2021 Oct 19;2(10):100410. doi: 10.1016/j.xcrm.2021.100410. eCollection 2021 Oct 19."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Omalizumab Group",
          "description": "Patients will receive omalizumab.\n\nOmalizumab: subcutaneous injection"
        },
        {
          "id": "FG001",
          "title": "Placebo",
          "description": "Patients will receive placebo.\n\nplacebo: subcutaneous injection"
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "28"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "8"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "24"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "2"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "6"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Adverse Event",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Lack of Efficacy",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "6"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Omalizumab Group",
          "description": "Patients will receive omalizumab.\n\nOmalizumab: subcutaneous injection"
        },
        {
          "id": "BG001",
          "title": "Placebo",
          "description": "Patients will receive placebo.\n\nplacebo: subcutaneous injection"
        },
        {
          "id": "BG002",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "29"
            },
            {
              "groupId": "BG001",
              "value": "8"
            },
            {
              "groupId": "BG002",
              "value": "37"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEDIAN",
          "dispersionType": "FULL_RANGE",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "10",
                      "lowerLimit": "7",
                      "upperLimit": "19"
                    },
                    {
                      "groupId": "BG001",
                      "value": "10",
                      "lowerLimit": "6",
                      "upperLimit": "17"
                    },
                    {
                      "groupId": "BG002",
                      "value": "10",
                      "lowerLimit": "6",
                      "upperLimit": "19"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "11"
                    },
                    {
                      "groupId": "BG001",
                      "value": "4"
                    },
                    {
                      "groupId": "BG002",
                      "value": "15"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "18"
                    },
                    {
                      "groupId": "BG001",
                      "value": "4"
                    },
                    {
                      "groupId": "BG002",
                      "value": "22"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Baseline population",
          "populationDescription": "One subject declined treatment after being randomized but before beginning treatment",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "29"
                    },
                    {
                      "groupId": "BG001",
                      "value": "8"
                    },
                    {
                      "groupId": "BG002",
                      "value": "37"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "6 weeks after last dose of omalizumab/placebo",
          "groups": [
            {
              "id": "OG000",
              "title": "Omalizumab Group",
              "description": "Patients will receive omalizumab.\n\nOmalizumab: subcutaneous injection"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Patients will receive placebo.\n\nplacebo: subcutaneous injection"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "29"
                },
                {
                  "groupId": "OG001",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "23"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "12 weeks after last dose of omalizumab/placebo",
          "groups": [
            {
              "id": "OG000",
              "title": "Omalizumab Group",
              "description": "Patients will receive omalizumab.\n\nOmalizumab: subcutaneous injection"
            },
            {
              "id": "OG001",
              "title": "Placebo",
              "description": "Patients will receive placebo.\n\nplacebo: subcutaneous injection"
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "29"
                },
                {
                  "groupId": "OG001",
                  "value": "8"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "20"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Omalizumab Group",
          "description": "Patients will receive omalizumab.\n\nOmalizumab: subcutaneous injection",
          "seriousNumAffected": 4,
          "seriousNumAtRisk": 28,
          "otherNumAffected": 28,
          "otherNumAtRisk": 28
        },
        {
          "id": "EG001",
          "title": "Placebo",
          "description": "Patients will receive placebo.\n\nplacebo: subcutaneous injection",
          "seriousNumAffected": 3,
          "seriousNumAtRisk": 8,
          "otherNumAffected": 8,
          "otherNumAtRisk": 8
        }
      ],
      "seriousEvents": [
        {
          "term": "Anaphylaxis",
          "organSystem": "Immune system disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numEvents": 3,
              "numAffected": 3,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Psychiatric",
          "organSystem": "Psychiatric disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numEvents": 1,
              "numAffected": 1,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numEvents": 0,
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Abdominal Pain",
          "organSystem": "Gastrointestinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 10,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 5,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Allergic Rhinitis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Anaphylaxis",
          "organSystem": "Immune system disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 6,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Diarrhea",
          "organSystem": "Gastrointestinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 4,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Fever",
          "organSystem": "General disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 11,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 9,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Rash Maculo-Papular",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Sore Throat",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Upper Respiratory Infection",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Urticaria",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 8
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 28
            },
            {
              "groupId": "EG001",
              "numAffected": 2,
              "numAtRisk": 8
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictiveAgreement": false
      },
      "pointOfContact": {
        "title": "Lynda Schneider",
        "organization": "Boston Children's Hospital",
        "email": "lynda.schneider@childrens.harvard.edu",
        "phone": "617-355-6180"
      }
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D021183",
          "term": "Peanut Hypersensitivity"
        },
        {
          "id": "D005512",
          "term": "Food Hypersensitivity"
        }
      ],
      "ancestors": [
        {
          "id": "D000074924",
          "term": "Nut and Peanut Hypersensitivity"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "D000069444",
          "term": "Omalizumab"
        }
      ],
      "ancestors": [
        {
          "id": "D000888",
          "term": "Antibodies, Anti-Idiotypic"
        },
        {
          "id": "D000906",
          "term": "Antibodies"
        },
        {
          "id": "D007136",
          "term": "Immunoglobulins"
        },
        {
          "id": "D007162",
          "term": "Immunoproteins"
        },
        {
          "id": "D001798",
          "term": "Blood Proteins"
        },
        {
          "id": "D011506",
          "term": "Proteins"
        },
        {
          "id": "D000602",
          "term": "Amino Acids, Peptides, and Proteins"
        },
        {
          "id": "D061067",
          "term": "Antibodies, Monoclonal, Humanized"
        },
        {
          "id": "D000911",
          "term": "Antibodies, Monoclonal"
        },
        {
          "id": "D012712",
          "term": "Serum Globulins"
        },
        {
          "id": "D005916",
          "term": "Globulins"
        }
      ]
    }
  },
  "hasResults": true
}